4-Methyl-1-[2'-(pyrrolidine-1-sulfonyl)-biphenyl-4-ylmethyl]-piperidin-4-ol | 1202647-53-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Methyl-1-[2'-(pyrrolidine-1-sulfonyl)-biphenyl-4-ylmethyl]-piperidin-4-ol
• 英文别名: 4-Methyl-1-[[4-(2-pyrrolidin-1-ylsulfonylphenyl)phenyl]methyl]piperidin-4-ol
• CAS: 1202647-53-7
• 化学式: C₂₃H₃₀N₂O₃S
• 分子量: 414.569
• InChiKey: IUUQUKZJLCZUEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  69.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(2-溴苯基磺酰)吡咯啉 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 三乙酰氧基硼氢化钠 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 22.0h， 生成 4-Methyl-1-[2'-(pyrrolidine-1-sulfonyl)-biphenyl-4-ylmethyl]-piperidin-4-ol
  参考文献：
  名称：

  Design and Discovery of a Selective Small Molecule κ Opioid Antagonist (2-Methyl-N-((2′-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242)

  摘要：

  By use of parallel chemistry coupled with physicochemical property design, a series of selective kappa opioid antagonists have been discovered. The parallel chemistry strategy utilized key monomer building blocks to rapidly expand the desired SAR space. The potency and selectivity of the in vitro kappa antagonism were confirmed in the tail-flick analgesia model. This model was used to build an exposure-response relationship between the kappa K-i and the free brain drug levels. This strategy identified 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242, which entered phase 1 clinical testing and has demonstrated target engagement in healthy volunteers.

  DOI：

  10.1021/jm2006035

文献信息

• Diaryl Compounds and Uses Thereof
  申请人：Verhoest Patrick

  公开号：US20100035873A1

  公开（公告）日：2010-02-11

  The invention relates to derivatives of a compound of formula I: wherein R 1 to R 7 and X 1 to X 6 are as defined herein. The invention relates to the uses thereof for treating diseases, conditions and/or disorders mediated by kappa opioid receptors (KORs). Specifically, the compounds are selective antagonists of KORs and are highly selective to KORs relative to mu and delta opioid receptors.

  本发明涉及公式I的化合物的衍生物：其中R1至R7和X1至X6的定义如本文所述。本发明涉及其用于治疗由kappa阿片受体（KORs）介导的疾病、状况和/或障碍的用途。具体而言，这些化合物是KORs的选择性拮抗剂，并且相对于mu和delta阿片受体高度选择性地作用于KORs。